UNSPSC 51334316: Zuclopenthixol hydrochloride

This classification denotes the hydrochloride form of an antipsychotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 47ISU063SG. European Medicines Agency schedules Zuclopenthixol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00195MIG. Zuclopenthixol generally arises in the molecular formula C22H25CLN2OS.

UNSPSC 51334316 Zuclopenthixol hydrochloride is a Commodity code that nominally names a specific antipsychotic pharmaceutical, but recent state and local procurement activity under this code shows minimal direct alignment with that narrow drug scope. The available recent opportunities tagged to this code instead reflect broader pharmaceutical and health-supply procurement: naloxone and drug deactivation systems for community health support, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals distributed through state and local health systems. Issuing bodies span county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and cooperative purchasing alliances serving multiple states and localities (Minnesota Multistate Cooperative Purchasing Alliance). The code shows activity from health departments, state pharmacy benefit programs, and cooperative purchasing vehicles rather than a concentrated procurement stream tied to zuclopenthixol specifically.

Geographic spread across the recent activity includes Florida, Texas, and Minnesota, with the cooperative purchasing vehicle serving Oregon and other participating jurisdictions. Representative recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026; due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription programs to improve pharmacy benefit management; and the Minnesota Department of Administration's MMCAP RFP S1070000015802 (posted January 20, 2026; due March 26, 2026) establishing contracts for generic multi-source pharmaceuticals and OTC products across state and local facilities. The mismatch between the code's nominal drug name and the actual procurement scope suggests that this code may be underutilized or misapplied in state and local procurement systems for pharmaceutical buys.